157 25 : 157 164 2011 Probiotic products, Historical Background and Development in Future Yoshinori UMESAKI* *Yakult Central Institute for Microbiological Research Abstract Probiotic products are currently often encountered in our daily life as well as the term Probotics. The prevalence of probiotic products is not confined to Japan but extends throughout the world due to individuals interest in health based on scientific information. At this point, I would like to look back at the historical background behind the prevalence and globalization of probiotic products, including their concept and the alteration of the definition of probiotics, and think about the scientific aspects of probiotics on the way to biomedical development, starting from the improvement of intestinal disorders by feeding fermented milk and yogurt or bacterial preparation as supplements. Finally, I would like to consider the future of probiotics in relation to the regulation of health claims about probiotic products, which will affect the direction of development of probiotics. Key words : probiotic products ; historical background ; health claim ; medical application 1935 1796 Yaho, Kunitachi- 2011 5 18 186 8650 1796 shi, Tokyo 186 8650, Japan 1970
158 25 3 2011 L. bulgaricus 1930 Lactobacillus casei YIT9029 for life Fuller 1 2002 WHO/FAO 2 3 Lactobacillus casei 1970 1. L. casei 4 PCR 5 2.
159 1980 ph 4 6 7 1990 L. casei TNO 8 1899 Tissier 1 9 10 1971 B. longum BB536 L. acidophilus 1978 B. longum BB536 B. breve B. bifidum L. acidophilus C. difficle Table 1 1. 1970 11 2 Clostridium Bacteroides 12
160 25 3 2011 Table 1. Transit ph NK IBS IBS I IBD / II Well-being IBS Histone Deacetylase 13 2. IBD UC CD 8 210 5 IL-2 IL-10 UC SAMP1/Yit 14 IBD IBD
161 8 15 UC IBD IBD IBD 16 IBD IL-10 Lactococcus lactis 17 3. CD4 T Th1 Th2 2005 Th17TTreg T T 18 IgE Th2 IFN-γ Th1 Th2 B. longum BB536 Th1/Th2 19 Lactobacillus rhamnosus GG Lancet 20 IBD Th17 21 4. 10 20 IBS IBS IBS Rome II Rome III 22IBS IBS IBD L. acidophilus 23
162 25 3 2011 5. SIRS H. pylori 60 70 H. pylori Lactbacillus gasseri OLL 2716 24 Fuller SCFA SIRS 6. EU 2006 EU 13.1 13.5 14 13.5 1
163 GRAS Generally Recognized as Safe Substances FDA 25 1 Fuller R. 1989. Probiotics in man and animals. J Appl Bacteriol. 66 : 365 378. 2 Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, 2002, London, Ontario. 3 Guarner F, Schaafsma GJ. 1998. Probiotics, Int J Food Microbiol 39 : 237 238. 4 1966 1 L. acidophilus strain Shirota21 : 274 283. 5 Fujimoto J, Matsuki T, Sasamoto M, Tomii Y, Watanabe K. 2008. Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA. Int J Food Microbiol 126 : 210 215. 61980 7 Hangate RE, 1969, Methods in Microbiology. p.117. Academic Press. New York. 8 Spanhaak S, Havenaar R, Schaafsma G. 1998. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 52 : 899 907. 91978 10 Benno Y, Sawada K, Mitsuoka T. 1984. The intestinal microflora of infants: composition of fecal flora in breastfed and bottle-fed infants. Microbiol Immunol 28 : 975 986. 11 Mastromarino A, Reddy BS, Wynder EL. 1976. Metabolic epidemiology of colon cancer: enzymic activity of fecal flora. Am J Clin Nutr 29 : 1455 1460. 12 Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 : 1016 1022. 13 Garcea RL, Alberts BM. 1980. Comparative studies of histone acetylation in nucleosomes, nuclei, and intact cells. Evidence for special factors which modify acetylase action. J Biol Chem 255 : 11454 11463. 14 Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y. 1998. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43 : 71 78. 15 Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebocontrolled trial. Gastroenterology 119 : 305 309. 16 C, Yan F, Polk DB. 2008. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14 : 1585 1596. 17 Bermúdez-Humarán LG. 2009. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 5 : 264 267. 18 Ng S, Hart A, Kamm M, Stagg A, Knight S. 2009. Mechanisms of action of probiotics: Recent advances. Inflammatory Bowel Diseases 15 : 300 310. 19 Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, Iwatsuki K, Kokubo S, Togashi H, Enomoto K, Enomoto T. 2006. Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial. J Investig Allergol Clin Immunol 16 : 86 93. 20 Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. 2003. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled
164 25 3 2011 trial. Lancet 361 : 1869 1871. 21 Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139 : 485 498. 222006 Rome III 64 : 1425-1428. 23 Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13 : 35 37. 24 Tamura A, Kumai H, Nakamichi N, Sugiyama T, Deguchi R, Takagi A, Koga Y. 2006. Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. J Gastroenterol Hepatol 21 : 1399 1406. 252011 22 : 26 37.